Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western hemisphere and mainly affects elderly patients. No curative treatment is currently available for this disease. Advanced disease is treated according to the patients' fitness and comorbidity burden as well as according the presence of high risk genetic factors in CLL cells. The detection of del(17p) and/or TP53 gene mutations reflects a very unfavorable prognosis and refractoriness to chemotherapy (very high risk CLL). In physically fit patients without high comorbidity burden and without very high risk prognostic factors, chemoimmunotherapy containing fludarabine, cyclophosphamide, and the CD20 antibody rituximab (FCR) is standard therapy because this regimen has been shown to improve overall survival. In patients with significant comorbidity burden, a less intense chemoimmunotherapy regimen should be administered consisting of the alkylating agent chlorambucil plus CD20 antibody. In very high risk patients, kinase inhibitors blocking the signaling transduction pathway of the B cell receptor have been approved since 2014. The same substances are also approved in relapsed CLL. However, in relapsed CLL repetitive administration of chemoimmunotherapy is ...Continue Reading
References
Jul 1, 1981·Cancer·J L BinetF Gremy
Aug 1, 1996·Leukemia & Lymphoma·M HallekB Emmerich
Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Jan 25, 2008·Blood·Michael HallekUNKNOWN International Workshop on Chronic Lymphocytic Leukemia
Aug 9, 2008·The New England Journal of Medicine·Andy C RawstronPeter Hillmen
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaUNKNOWN Hx-CD20-406 Study Investigators
Jul 3, 2010·Blood·Peter DregerUNKNOWN German CLL Study Group
Oct 5, 2010·Lancet·M HallekUNKNOWN German Chronic Lymphocytic Leukaemia Study Group
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Dec 14, 2011·The New England Journal of Medicine·Lili WangCatherine J Wu
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Oct 9, 2012·Leukemia·A C RawstronUNKNOWN European Research Initiative in CLL
Dec 28, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier C BadouxAlessandra Ferrajoli
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jul 9, 2013·Seminars in Cancer Biology·Federico Caligaris-CappioCristina Scielzo
Dec 18, 2013·The Lancet Oncology·Susan O'BrienJohn C Byrd
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenChristopher F E Pocock
May 7, 2014·Blood·Natali PflugMichael Hallek
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)